Clinical trial · Interventional
Bronchoscopic Laser Ablation of Peripheral Lung Tumors
Bronchoscopic Laser Ablation of Solid Peripheral Lung Tumors Followed by Surgical Resection (BLAST-SR Trial)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Very slow accrual rate
Summary
Brief summary (as posted)
As our population ages and we diagnose early lung cancer in patients who cannot undergo surgery due to multiple medical conditions, there is growing interest in minimally invasive modalities to treat these tumors. In this study we are assessing the ability of bronchoscopic laser ablation to kill the cancer cells in these tumors. Patients will undergo bronchoscopy (a tube-like instrument inserted through the mouth to view the inside of the trachea, air passages, and lungs). A thin catheter will be passed through the wind-pipes and into the lung tumor with computed tomography guidance. A laser probe is then passed through this catheter and it is used to destroy the tumor with heat. Patients will then undergo lung surgery with resection of the tumor, and the resected specimen will be reviewed to describe the amount of tumor-kill produced by the laser.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Carcinoid Tumor | Lung Neuroendocrine Tumor | ALIAS | 0.90 |
| Lung Non-Small Cell Carcinoma | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.80 |
| Metastatic Lung Carcinoma | Lung Carcinoma | CURATED_BROADER | 0.78 |
| Stage IVA Lung Cancer AJCC v8 | Malignant Lung Neoplasm | CURATED_BROADER | 0.78 |
| Stage IVB Lung Cancer AJCC v8 | Malignant Lung Neoplasm | CURATED_BROADER | 0.78 |
| Stage IV Lung Cancer AJCC v8 | Malignant Lung Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cone-Beam Computed Tomography | Procedure | — | UNRESOLVED |
| Conventional Surgery | Procedure | — | UNRESOLVED |
| Laser Ablation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Diagnostic (bronchoscopic laser ablation, CBCT)
- description
- Patients undergo bronchoscopic laser ablation following standard bronchoscopy and endobronchial ultrasound. Patients also undergo CBCT before and after laser ablation. 48-72 hours after the procedure, patients undergo standard surgical resection of the lung tumor.
- interventionNames
- Procedure: Cone-Beam Computed Tomography
- Procedure: Conventional Surgery
- Procedure: Laser Ablation
Primary outcomes (1)
- measure
- Pathologic Changes From Bronchoscopic Laser Ablation of Peripheral Lung Tumors
- timeFrame
- Up to 16 months
- description
- Pathologic changes will be categorized into three groups: 1. Complete Ablation: absence of staining (anti-mitochondria antibody \[MAB\] 1273 or nicotinamide adenine dinucleotide-hydrogen \[NADH\], or both) of tumor cells. 2. Quasi-Complete Ablation: positive staining of 10% of tumor cells. 3. Incomplete ablation: positive staining in \> 10% of tumor cells. Will conduct extensive descriptive analyses of the data collected. Will calculate the appropriate summary statistics and 90% confidence intervals (CIs) for the measures of interest.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Written informed consent * Performance status 0-2 (Eastern Cooperative Oncology Group classification) * Subject is considered a candidate for bronchoscopy * Subject is considered a candidate for surgery (other lobar or sub-lobar resection) based on radiographic staging and functional evaluation * Lung lesion that is either biopsy-proven cancer or is suspicious for cancer * Both non-small cell lung cancer (including carcinoid tumors) and metastatic disease * The lesions should be: =\< 3 cm, located in the outer 2/3 of the lung, and leave \>= 1 cm of tumor-free lung parenchyma between target tumor and pleura or fissure Exclusion Criteria: * Tumors greater than 3 cm, located in the inner 1/3 of the lung, invading a major vessel, or located \< 1 cm from the pleural or fissure * Tumors qualified as non-resectable * Tumors that cannot be reached bronchoscopically * Patients declared non-surgical candidates * Patients who are not candidates for bronchoscopy * Patients with lung cancer who are found to have N2-3 disease * Patient with lung metastases who are found to have any malignant mediastinal lymph node * Patients in which the target lesion is confirmed as benign or small cell lung cancer * Patients without a prior diagnosis of the target lesion whose diagnosis cannot be made during bronchoscopy * Patients who have received chemotherapy within 60 days prior to bronchoscopic laser ablation * Patients who were previously treated for the target lesion * Pregnant patients
References
Publications (0)
Data not yet available